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ABSTRACT
IDENTIFICATION OF IMMUNOMODULATORY CELLS INDUCED
BY 670 NM LIGHT THERAPY IN AN ANIMAL MODEL OF
MULTIPLE SCLEROSIS

by

Erin C. Koester

The University of Wisconsin-Milwaukee, 2013
Under the Supervision of Dr. Jeri-Annette Lyons

Multiple sclerosis is an autoimmune, demyelinating disease characterized by
neurodegeneration and inflammation of the central nervous system.

It affects

approximately 250,000 people in the United States alone, with women being affected two
times more than men.

Experimental Autoimmune Encephalomyelitis (EAE) is the

primary animal model of MS, sharing clinical signs and histopathology with MS. The
current paradigm supports MS/EAE induction by myelin reactive CD4+ T cells that cross
the blood brain barrier to induce an inflammatory response that leads to the destruction of
the myelin sheath and eventual loss of axons. Recent data suggest that axonal loss and
disease progression are due to accumulation of oxidative stress. Most of the current
therapies for MS are only useful early in the disease process, slowing disease progression
but not preventing it, probably because they do not affect oxidative stress. With previous
studies showing relevance of mitochondrial dysfunction to neurodegeneration, new
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therapies designed to maintain mitochondrial function could prove beneficial.
Photobiomodulation is an alternative therapy proven effective in the treatment of chronic
inflammation and neurodegeneration.

Previous data demonstrated that 670nm near-

infrared (NIR) light-emitting diode (LED) is effective in the amelioration of the disease
in a mouse model of MS. Furthermore, experiments suggested an important role for antiinflammatory cytokines, particularly Interleukin-10 (IL-10), and maintenance of
mitochondrial function as important mechanisms mediating disease amelioration. The
current studies sought to characterize the immune cell population induced by
photobiomodulation which is responsible for the clinical effect noted. With a deeper
understanding of the mechanism of protection against disease, the 670nm light would be
a promising adjunct therapy for the treatment of MS.
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CHAPTER I: INTRODUCTION
Multiple Sclerosis
Multiple sclerosis (MS) is a disease of unknown etiology characterized by
inflammation, loss of myelin, axonal damage, and neurodegeneration of the central
nervous system (CNS) [1]. MS is thought to be a CD4+ T cell-mediated autoimmune
disorder [2]. It affects an estimated 250,000 people in the United States alone [3]. As
seen with many autoimmune disorders, MS plagues more females than males and is
typically diagnosed between 20 to 40 years of age [1]. While the general etiology of the
disease is unknown, MS affects genetically susceptible individuals, with contribution
from environmental factors [4].
The symptoms of MS, including sensory disturbances, memory loss, double
vision, muscle weakness and paralysis, vary from individual to individual making it a
difficult disease to diagnose [5]. Paralysis and loss of function are hallmark symptoms
of MS seen in advanced stages of the disease. Studies suggest that a cascade of events
beginning with mitochondrial dysfunction and immune infiltration lead to axonal loss
that contributes to MS pathology and disease progression [6].

While current therapies

exist to slow disease progression and to treat the symptoms of the disease, the overall
goal of lasting disease amelioration has yet to be realized.
Three main clinical phenotypes of MS have been identified: relapsing-remitting
MS (RR-MS), primary progressive MS (PP-MS), and secondary progressive MS (SPMS) [1]. The majority of patients display RR-MS in the beginning stages of the disease.
This phenotype is characterized by bouts of acute inflammation, resulting in neurological
dysfunction, followed by periods of remission [3,7]. Typically, RR-MS patients enter
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into the SP-MS within in 5-10 years of diagnosis, characterized by progressively worse
disease without the relief of remission. Finally, approximately 15% of MS patients have
PP-MS. From the onset of PP-MS, patients experience a progressively worse disease,
which in severe cases can be quite rapid, again without any bouts of remission [3, 4]. It
is not clear, however, the exact factors that trigger the disease into these distinct disease
courses [4]. Figure 1 shows a representation of the typical disease course associated with
each clinical phenotype [8].

1. Graphical
representation
of the 3 mainof
clincial
of MSphenotypes of MS.
Figure
1. Graphical
representation
the 3phenotypes
main clinical

Experimental Autoimmune Encephalomyelitis
Much has been learned about the pathogenesis of MS through experiments in the
Experimental Autoimmune Encephalomyelitis (EAE) animal model. EAE is also
routinely used to identify therapeutic targets and to investigate novel therapies [9]. EAE
mimics the clinical signs, histopathology, and disease mechanisms associated with MS.
The clinical course of EAE presents as bouts of partial to full hind-limb paralysis,
progressing to forelimb involvement with severe disease. Like MS, EAE is a CD4+ T
cell-mediated demyelinating disease of the CNS. The disease is initiated through active
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immunization using myelin basic protein (MBP), proteolipid protein (PLP), or myelin
oligodendrocyte glycoprotein (MOG) [10] emulsified in an adjuvant that will promote an
inflammatory response to the myelin proteins [11]. PLP and MBP are major constituents
of myelin, located internally, important to maintaining the structural integrity of the
myelin sheath, whereas MOG, a minor contributor to myelin, is a type I transmembrane
protein located on the outer surface of the myelin sheath and oligodendrocytes [12-14].
Due to its external location, MOG is considered a candidate antigen for the initiation of
MS/EAE, whereas PLP and MBP are thought to be important to disease progression or
relapse [14]. Several studies using anti-MOG antibodies have supported its role as an
important auto-antigen in demyelinating CNS diseases.
Similar to MS, the EAE disease course varies depending on the species, strain and
antigen used. Each of these different models previously mentioned is considered a model
of the stage of MS that it mimics. For example, disease in Lewis rats is an acute,
monophasic disease, while disease in SJL mice presents as a relapsing/remitting disease
reminiscent of the early stage of MS in patients. EAE in C57BL/6 mice, initiated with
MOG35-55, used in the proposed studies, presents as a chronic relapsing/progressive
disease similar to the chronic phase noted in established MS patients. Figure 2 depicts
disease course based on species, strain, and peptide used. Auto-antibodies reactive to
MOG contribute to the immunopathological mechanisms of the disease, including
demyelination and axonal loss with the CNS [12,13].
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Figure 2. Disease course based on species, strain, and antigen used for onset of disease.
2. Disease course based on species, strain, and antigen used for onset of disease

Immunopathogenesis of MS/EAE
Autoimmunity
In a healthy individual, CD4+ T cells regulate the immune system. In the case of
autoimmunity, the body cannot distinguish between self and non-self, thus creating an
immune response to its own cells and tissues. Typically, autoreactive T cells with a high
affinity toward self-peptide are eliminated during maturation within the thymus, termed
“central tolerance” [15]. When these autoreactive T cells evade deletion, autoimmunity
may occur.

In healthy individuals, these cells remain in a quiescent state, termed

“peripheral tolerance”. Multiple mechanisms of peripheral tolerance have been proposed
[16]. Similarly, multiple mechanisms have been proposed by which tolerance is broken,
leading to the onset of autoimmunity [16-19].
One hypothesis is put forth to explain the onset of autoimmunity is molecular
mimicry. In this case, small pathogenic peptide fragments that share similar structures or
sequences as self-antigens are delivered onto the major histocompatibility complex
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(MHC) -class II molecules [15]. Similarly, this results in reactivity toward self-antigens
and elicits a cascade of inflammation and neurodegeneration. Another hypothesis is that
autoimmunity, including MS, is initiated through a viral infection. Theiler’s murine
encephalomyelitis virus (TMEV) is a CD4+ T cell-mediated demyelinating disease that
mimics MS-like symptoms [17, 18]. In this model, low levels of the infectious virus can
be detected months after inoculation within the CNS [18]. Demyelination is brought on
by virus-specific Th1 cells and autoreactive T cells are stimulated containing virusencoded superantigens [17]. The final hypothesis put forth is epitope spreading. Epitope
spreading occurs when epitopes, distinct from the epitope inducing the disease, become
reactive during chronic inflammation [19]. In this case, encephalitogenic myelin proteins
are primed secondary to myelin destruction with CD4+ T cells specific for multiple
epitopes [19]. These three hypotheses are represented in Figure 3. While all of these are
plausible explanations of the evolution of MS, it is most likely the combination of the
factors that play a role in disease initiation and progression [15].

Figure 3. Plausible explanations for autoimmunity in MS/EAE
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T cells
The role of T cells in the pathogenesis of MS/EAE was introduced over 30 years
ago by Ben-Nun et al. through the adoptive transfer of T cells specific for CNS autoantigens [20, 21]. Extensive research supports the understanding that MS/EAE are
initiated by MHC class II restricted, myelin-reactive CD4+ T cells [4, 7, 22]. These cells
are activated in the periphery and infiltrate the CNS, leading to disease pathology [23].
Effector T helper (Th) cells are responsible for secretion of cytokines, and are
further broken down into subsets, including but not limited to, Th1, Th2, and Th17 cells.
Th1 cells, generated in the presence of Interleukin (IL)-12 and IL-18, are characterized as
pro-inflammatory cells. This population of cells is defined by secretion of proinflammatory cytokines, IL-2 and Interferon-gamma (IFN-γ) [20, 23]. These are
cytokines that play a central role in initiation of encephalitogenic T cells, as wells as the
progression of CNS inflammation in MS and animal models [23, 24]. Differentiation
into the Th2 subset occurs in the presence of IL-4. These cells are considered antiinflammatory and are known to be protective in EAE/MS [25]. This population is
characterized by the secretion of the cytokines, IL-4, IL-5, IL-13, and IL-10. It has been
recently hypothesized that Th17 cells also play a large role in MS pathology [26]. This
population, induced in the presence of transforming growth factor beta (TGF-β) and IL-6,
secrete the pro-inflammatory cytokine IL-17 [27]. Together, Th1/Th17 plays a role in
MS induction and pathogenesis [27].
Th1 cytokines are responsible for the recruitment and activation of inflammatory
cells. IFN-γ is thought to be central in mediating the pathogenesis of MS/EAE. IFN-γ
facilitates the activation of macrophages. It is a pro-inflammatory cytokine that drives a
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chronic inflammatory pathway leading to tissue injury [28]. However, the understanding
of the role of IFN in the disease process is confounded by the observation that the
deletion of IFN-γ does not eliminate the disease but increases the clinical disease and
pathology [24]. This exacerbation is not only seen in EAE, but in other Th1 autoimmune
conditions such as experimental autoimmune uveitis [24]. This finding indicates that
IFN-γ is not only responsible for disease progression, but also aids in the regulatory
functions of the immune system.
Tumor necrosis factor-α (TNF-α) is typically released in response to a bacterial
infection and is associated with a Th1 cell response eliciting CNS inflammation. Like
IFN-γ, however, the mice deficient of this cytokine go on to develop a worse disease than
their wild-type (WT) counterparts [25]. In a study by Probert et al. over-expression of
TNF-α has also been found to be cytotoxic to oligodendrocytes resulting in severe
demyelination [29].
Elevated levels of IL-17, produced from Th17 cells, have also been established in
MS patients [30]. A study by Komiyama et al. demonstrates the pathogenic role that IL17 plays in MS/EAE. Mice deficient in IL-17 display a less severe disease course than
WT mice, indicating that IL-17 plays an important role in the development of EAE.
Interestingly, mice devoid of IFN-γ had higher IL-17 production compared to the WT
controls. This further blurs the role of IFN-γ as it displays both pathogenic and protective
roles as a mediator of Th1 cells as well as a suppressor of IL-17 cytokines [31].
Recent data suggest that chronic inflammatory diseases such as MS, Th1 cells
play a pathogenic role, whereas Th2 cells display protective qualities [32]. Th2 cells
counter the roles of Th1 cells through the release of anti-inflammatory cytokines that aim
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to down-regulate the production of pro-inflammatory cytokines. Th2 cells are protective
in both MS and EAE through the release of IL-10 as well as another anti-inflammatory
cytokine, IL-4. In addition to their anti-inflammatory processes, these cytokines also
inhibit the demyelinating functions of macrophages [32]. In past studies, patients
exhibiting elevated levels of Th2 cells due to parasitic infections have shown milder
forms of MS [23]. Fleming and Fabry have proposed the use of parasites as a therapy for
autoimmune diseases due to the increased production of Th2 they afford [33].

A

representation of a naïve T cell into its effector and suppressive subsets is seen in Figure
4.

Figure 4. Cytokines involved and secreted in the differentiation of T cells.

Secretion of IL-10, through subsets of regulatory B cells (Bregs) and regulatory T
cells (Tregs), aids in the regulation of the immune response. IL-10 mediates the response
through the inhibition of pro-inflammatory cytokines as well as causing T cell
hyporesponsiveness, or loss of T cell function. Its role as an anti-inflammatory cytokine
is further confirmed in IL-10 deficient mice. Induction of EAE in these knockout mice is
associated with a worse disease course compared to wild-type controls. Because these
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mice are lacking IL-10, the balance is shifted to a pro-inflammatory state resulting in a
worse disease course [34]. Furthermore, induction of IL-10 in current MS therapies
proves to be an effective means to ameliorate the disease [35].
IL-4, like IL-10, is an anti-inflammatory cytokine as it amplifies the response of
Th2 cells. Through the inhibition of Th1 cells, it decreases the production of TNF-α and
IFN- [25]. Th1 and Th2 cells play antagonistic roles. Altering disease course from
being Th1-dominated to being Th2-dominated typically result in positive clinical effects
for the MS and EAE [36].

B cells
While the specific role of B cells in MS/EAE pathology remains unclear, they are
thought to play a role in the disease process. B cells reactive to MOG have been found in
the CNS of MS patients [37]. B cells, upon antigen challenge, differentiate into plasma
cells and produce antibodies. Antibodies for myelin components are present in the
cerebral spinal fluid (CSF) of MS patients [37]. Oligoclonal immunoglobulin G (IgG)
bands (OCBs) are found within the CSF are present in 95-100% of MS patients and
represent immunoglobulin synthesized within the CNS.

The presence of OCBs is

typically associated with a worse disease prognosis [37]. A study by Lucchinetti et al.
indicates that high numbers of antibody deposits and complement activation are
characteristic of demyelinated lesions found through histopatholigical studies of MS
patients [38]. The activation of complement lends a hand to demyelination through
pathogenic antibodies as well as antibody-mediated functions [39-42].
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Regulatory Immune Cells
Regulatory T cells
The involvement of regulatory T cells (Tregs) in autoimmune disorders is still
under debate [43]. While autoreactive T cells are found in all individuals, those with
autoimmunity exhibited low levels or dysfunctional CD4+ Tregs [43-45]. A study done
by Viglietta et al. demonstrated reduced numbers of CD4+ Tregs in MS patients
compared to the healthy controls [44]. Contradictory studies have been publish which
show no difference in the number of circulating Tregs, however, the suppressive
functions of the Tregs seem to be decreased within the patient population in comparison
to the healthy controls [43]. Whatever the case may be, these studies indicate the
functional role of these cells in protection against an autoimmune response.
In contrast from effector Th cells, Tregs are responsible for the down-regulation
of antigen-specific T-cell responses and are important in the prevention of autoimmunity.
In the thymus, autoreactive T cell clones with high avidity are eliminated through
negative selection mediated by programmed cell death [46]. The autoreactive cells that
escape clonal deletion within the thymus and enter the peripheral circulation are those
responsible for the onset of autoimmunity. While exact mechanisms are unknown, Tregs
in EAE display protective qualities by increasing the Th2 phenotype toward an antiinflammatory state [46].
Forkhead box P3 (FoxP3) is an X-linked transcription factor considered to be the
most specific marker of Tregs [46]. The gene was originally found in scurfy mice in
which the gene was mutated. These mice possess a mutated FoxP3 gene, leading to a
fatal lymphoproliferative autoimmune disorder in these mice [43]. In transgenic mice
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with a targeted disruption of the FoxP3 gene (and subsequently CD4+CD25+ cells), an
almost identical condition was noted [43]. Thus, FoxP3 is considered to be a master
regulatory molecule in Tregs [46].
The regulatory activity of CD4+ T cells is seemingly increased with high
expressions of the surface marker CD25 [47] in natural Tregs (nTreg), or CD4+CD25+ T
cells that develop and mature in the thymus for immune regulation [23]. These nTregs
that express CTLA-4 (cytotoxic T cell lymphocyte antigen 4) and CCR4 (chemokine
receptor) arise from previously activated cells [48] and acquire FoxP3 expression during
maturation within the thymus [49].
Induced Tregs (iTreg) are CD4+CD25- T cells that acquire CD25 and FoxP3
expression in the periphery instead of the thymus in response to inflammation or
autoimmunity [48]. These Tregs constitute ~5-10% of circulating CD4+ T cells [43].
iTregs are induced with IL-2 and TGF-β [48]. While they have a similar phenotype as
nTregs, these cells arise from naïve CD4+ T cells [48]. These cells are responsible for the
secretion of the anti-inflammatory cytokine, IL-10, relevant to the decrease of MS
severity [23].
While they function quite differently, there is a link between Th17 cells and
Tregs. Wahl et al. was the first to show the importance of TGF-β in Treg development.
TGF-β is required for the differentiation of both T cell lineages (Figure 5). However, IL-6
is also needed for Th17 production [49]. The dichotomy between Th17 and Treg cells is
regulated at the transcriptional level. The transcription factor RORγt is required for
Th17cells whereas Tregs require FoxP3 [49-51]. In findings from Zhou et al. FoxP3,
from iTregs, has the ability to suppress RORγt, however, in the presence of IL-6, this
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suppressive activity is abrogated [49, 51]. Additionally, iTregs are resistant to the effects
of IL-6 and display a noticeable decrease of IL-6 receptors on their surface compared to
nTregs [48]. From a study done using green fluorescence protein (GFP) cells from
FoxP3-/- mice indicates that activation of nTregs with IL-6 results in a markedly
decreased FoxP3 expression [48]. After treatment with IL-6, these nTregs were unable to
increase the survival rate of mice with graft versus host disease [48]. In the presence of
IL-2, however, there is a down-regulation of IL-6 receptor expression and signaling [48].
These studies demonstrate the importance of the environment in which T cell activation
occurs.

Figure 5. Differentiation between Tregs and TH17 with the induction of IL-6.

The role of CD8+ Tregs has been overlooked since the emergence of CD4+ Treg
involvement in autoimmunity. CD8+ Tregs are also important in the suppression of
MS/EAE. Through the secretion of IL-10, CD8+ Tregs directly control the production of
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IFN-γ and the proliferation of CD8+ effector cells without the use of antigen presentation
[52]. While the exact role of FoxP3 is not understood, recent studies have shown FoxP3
expression in CD8+ T cells occurs after antigen activation affording suppressive activity
[53]. Because the role of CD8+ Tregs has not been extensively studied as CD+ Tregs, the
distinctive cellular markers are not fully known [52].

Correale and Villa found that

CD8+ Treg specific clones that recognize and lyse myelin-reactive CD4+ T cells
responsible for the induction of MS, are down-regulated in MS patients, specifically
within the CSF [52, 54]. Supporting this finding, lymph cells retrieved from immunized
mice revealed high populations of CD8+ Tregs when analyzed using flow cytometry [54].

Regulatory B cells
Regulatory B cells (Bregs) also act as regulators of the immune response through
the release of IL-10 [40, 41]. Bregs secrete cytokines that down-regulate the function of
autoreactive T cells as well as inflammation [40]. A study by Matsushita et al. proposes
that Bregs reduce disease severity during EAE initiation and Tregs inhibit the late stage
effects of MS [40]. In this study, the depletion of Bregs before and during disease
initiation led to increased disease severity, whereas depletion of Bregs after the
immunization had no effect on the disease severity [40]. Conversely, Treg depletion
before EAE onset delayed onset by 2 days and did not significantly disturb the severity,
however, depletion of Tregs after onset resulted in a significantly worse disease course
[40]. The exact interactions of B cells and Tregs in the activation and progression of the
disease remain unknown [40, 41].
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Role of Mitochondria
Evidence suggests that mitochondrial dysfunction actively contributes to axonal
injury and neurodegeneration [55]. The mitochondria, or the “power house” of the cell,
serve a variety of functions, including regulation of the electron transport chain,
adenosine-triphosphate (ATP) synthesis, ion homeostasis, lipid metabolism and apoptosis
[56, 57]. ATP synthesis mainly occurs within the inner membrane of the mitochondria
consisting of the electron transport chain [58]. While low levels of reactive oxygen
species (ROS) are generated by the mitochondria through oxidative phosphorylation,
mitochondrial antioxidant enzymes are produced to effectively remove these by-products
[58].
The mitochondrial membrane houses the electron transport chain. This chain is
responsible for the production of ATP within the cell. The chain is made up of 4
transmembrane complexes known as Complex I, Complex II, Complex III, and Complex
IV [59]. Throughout the transport chain, protons are translocated across the membrane to
produce a proton gradient. The electron flow travels throughout the other complexes
where it meets up with the final electron acceptor, oxygen. From here hydrogen and
oxygen combine to form a water molecule. The proton gradient generated is then used
for ATP production via oxidative phosphorylation [59]. Axonal injury and mitochondrial
defects, due to MS, occur within each of these complexes. These defects are responsible
for excessive ROS and loss of ion homeostasis [55]. When ion homeostasis is lost and
energy demands exceed ATP production, the balance of ion levels is lost eventually
resulting in axonal degeneration and progressive neurological disability [55].
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The mitochondrial free radical theory of aging (MFRTA) involves the generation
of potentially damaging ROS in the mitochondria [57]. This theory explains that the
mitochondria generate ROS that have damaging effects within all types of molecules
[57].

When the production of reactive oxygen species overwhelms the antioxidant

mechanism of the cell, oxidative stress leading to damage of proteins, lipids, and nucleic
acids occurs. This oxidative damage cannot be repaired [60, 61]. When oxidative
damage is excessive, signaling mechanisms are in place, which lead to the death of the
cell by apoptotic mechanisms [60].

Mitochondrial dysfunction is thought to play a

central role in oxidative damage leading to apoptosis [27].
Recent data suggest that accumulation of oxidative stress within the CNS plays a
critical role in the progression of MS/EAE [62, 63]. The current paradigm supports the
notion that MS initiation and myelin destruction are autoimmune in nature, while axonal
degeneration, mediated by accumulation of oxidative stress, is responsible for the
progression of the disease and the onset of permanent disability [62]. It was initially
thought that axonal degeneration coincided with bouts of inflammation. However, when
inflammation subsided, axonal degeneration persisted, indicating other factors were at
play [63]. A study done by Qi et al. showed that mitochondrial oxidative stress plays a
role in neurodegeneration before the infiltration of the inflammatory cells. This study
demonstrated that suppression of mitochondrial oxidative stress, which began before the
infiltration of inflammatory cells, ameliorates MS/EAE neurodegeneration [62]. The
increases of mitochondrial defenses against ROS suppressed the loss of the mitochondrial
membrane potential and protect the axon [62].
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With the loss of the myelin sheath surrounding the axon, sodium channels are
redistributed along the axon, and axonal transport becomes inefficient. Therefore, the
mitochondria are dispersed to the site of demyelination to maintain conduction [27,63].
With this localization, the mitochondria are exposed to large amounts of reactive oxygen
and reactive nitrogen species, such as nitric oxide (NO), which inhibits the function of
cytochrome c oxidase and cause mitochondrial DNA damage [63].

Initially, these

mitochondria are able to function at full capacity. However, eventually their function is
compromised [27], resulting in damage to the respiratory chain, leading to impairment of
ATP synthesis [63]. This has been noted in a study by Dutta et al. comparing the motor
cortex of six control patients in comparison to six MS patients. Their findings suggest
that diminished products from the electron transport chain in the MS patients, indicating
that mitochondria in these patients have limited capacities [64]. It is proposed that the
compromised mitochondria contribute to the axonal degeneration as well as neurological
disability within these MS patients [64].
FDA-approved therapies for MS exist to slow disease progression or manage
symptoms but do not stop it. These include immunomodulatory and immunosuppressive
therapies that work with RR-MS, however are less effective on later stages of the disease
[22]. This is presumably because they fail to address the mechanism of oxidative stress
and provide a neuroprotective component.

Photobiomodulation
Photobiomodulation (PBM), or low level light therapy (LLLT), uses light in the
far-red (FR) to near-infrared (NIR) range of 630-1000nm to regulate many cellular
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functions [65]. For over 40 years, light-emitting diodes (LED) and low-energy lasers
have been used to heal soft tissue injuries at an accelerated rate and to relieve chronic
inflammation [66]. Recently, it has also been proven beneficial in restoring or preserving
mitochondrial dysfunction, increasing energy metabolism, and improving cell viability
through the activation of cellular photoacceptors, such as cytochrome c oxidase, as well
as activation of transcription factors [22, 65, 67].
Within the mitochondria, a balance between ATP production and the production
of ROS must be met in order to prevent inflammation [61]. Several in vitro studies have
demonstrated an increase in ATP production in the presence of the light therapy [61].
While mitochondria produce increased amounts of ATP due to NIR-LED treatment, it is
also believed that PBM modulates ROS through a brief up-regulation, which induces
transcription factors [61, 68]. The induction of transcription factors are directly linked to
increased cell proliferation, modulation of cytokine levels, and inflammatory mediators
[68].
PBM uses the absorption of specific wavelengths of light to cause biological
changes within the cell through the activation of signaling pathways [69]. These effects
for PBM are mediated through improving energy metabolism and increasing ATP
production. In mammalian tissues, there are over 50 mammalian photoacceptors known
to absorb light within this range [67, 69]. Three major photoacceptor molecules are
hemoglobin, myoglobin, and cytochrome c oxidase [65]. Of these, cytochrome c oxidase
of the electron transport chain, is the only tissue associated with energy functions [65, 67,
69].

Up to 50% of NIR light administered to cells is absorbed by mitochondrial

chromophores, including cytochrome c oxidase [65]. Evidence of cytochrome c oxidase
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as a photoacceptor is also supported by experiments in which cytochrome c oxidase is
inhibited [66]. Action and absorption spectra have also been used as evidence for
cytochrome c oxidase as a photacceptor [66].

The absorption spectrum indicates

wavelengths of light in which light is removed from the spectrum, and the action
spectrum indicates the biological responses [66]. Because the absorption spectrum for
cytochrome c oxidase parallels that of the protective action spectrum of the FR/NIR
wavelengths, it is believed that cytochrome c oxidase is the primary terminal electron
acceptor of the mitochondrial electron transport chain [65, 67].
The exact mechanism by which the light influences cytochrome c oxidase has yet
to be elucidated; however it is believed that a link between NO and cytochrome c oxidase
is relevant [68]. Two pathways have been proposed as possible mechanisms for PBM
[61, 68, 70]. NO decreases cell respiration by binding to cytochrome c oxidase and
displacing oxygen [70]. PBM prevents binding of NO to cytochrome c oxidase through
the dissociation of NO to cytochrome c oxidase [68, 70]. High levels of NO have been
reported in cell cultures after PBM due to this dissociation [70]. The other plausible
explanation is that cytochrome c oxidase acts as a nitrite reductase enzyme to dissociate
the NO [68]. Both of these explanations result in increased ATP production [68].
The effect of PBM does not end with increased ATP production. It also affects
the production of ROS [70]. When oxygen, the final electron acceptor of the electron
transport chain, is metabolized, ROS are produced [68]. LLLT increases oxidation,
resulting in an increased number of ROS [68, 70]. This results in the induction of many
transcription factors, specifically nuclear factor kappa B (NF-κB) which transcribes
protective gene products that are anti-apoptotic and promote cell survival [70]. Figure 6
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is a representation of how PBM activates a cascade of events leading to transcriptional
changes and prevents cellular toxicity [68, 70].

Figure 6. LLLT dissociates NO increasing ATP production and increases ROS which drives
protection through the release of transcriptional factors, specifically NF-κB.

Because low doses of PBM are therapeutic, it has been argued that increasing the
dosage will have an increased beneficial effect.

While the topic is controversial,

evidence as pointed to the fact that PBM is dose dependent, and overexposure to light can
have detrimental effects [70]. At a low dose, PBM can enhance the proliferation of
lymphocytes through the increased release of growth factors [70]. At elevated levels,
PBM produces excessive ROS, excessive NO, and may activate a cytotoxic pathway all
of which may cause cell apoptosis [70]. At low levels, PBM initiates signaling through
cyclic AMP, but at increased doses mitochondrial permeability is compromised and
apoptosis is induced [70].
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Because MS/EAE pathogenesis is thought to be due, in part, to mitochondrial
dysfunction, this lab previously hypothesized that the use of PBM would prove beneficial
against disease progression [22]. Our published data indicate the effectiveness of once
daily 670nm NIR-LED treatment ameliorated EAE severity in female C57BL/6 mice.
Upon disease initiation, the mice were placed into two groups: 670nm light treated or
sham control, in which they were placed in the treatment chamber with no light
administration. In a blinded study, the mice were then graded using a clinical scale to
judge disease severity. A double treatment protocol was used in which mice received 7
days of treatment, or stress only restraint, followed by a 7-day rest period (in which no
light was administered), with a subsequent 7-day treatment and rest period. Figure 7
shows the influence the light therapy has by comparing the disease severity between
treated and control groups. The WT mice treated with the 670nm light show an improved
clinical score in comparison to the sham, or restraint only, counterparts.
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Figure 7. 670nm light reduces disease severity in MOG-induced mice. Treated mice
immunized withMOG35-55 following the double treatment protocol display decreased
disease severity in comparison to restraint only stress. (A)P<0.0001 by 2-way ANOVA
(Muili et al., 2012)

Again, using the double-treatment protocol, spinal cords were removed from
MOG35-55 immunized mice at 3 time points: 2 days post onset, peak, and 2 days after the
start of the second treatment. Interested in cytokine involvement in EAE, QPCR analysis
was done on IL-10 and IFN- γ. Figure 2 shows an up-regulation of IL-10 (Figure 8A)
during the chronic disease phase with a non-significant down-regulation of IFN-γ (Figure
8B) [22], suggesting a role for IL-10 in the protection from clinical EAE by 670nmmediated photobiomodulation.
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Figure 8: Cytokine modulation using the double-treatment protocol over the course of
EAE. Spinal cords were isolated from mice immunized with MOG35-55 receiving the doubletreatment protocol and QPCR was performed to look at cytokine expression. (A) IFN-Υ, (B)
IL-10.
(Muili et al., 2012)

Through use of the suppression protocol, in which mice were immunized with
MOG35-55 and treated for 10 consecutive days post immunization, the disease course of
WT mice were compared to IL-10-/- mice. In the findings from Muili et al, the WT mice
subjected to 670nm light treatment developed less severe EAE in comparison to the WT
mice that received restraint only stress, in which no light was administered (Figure 9A).
This is indicative of a possible neuroprotective role afforded through light therapy. In
contrast, IL-10-/- mice show no improvement in both 670nm treated and sham groups
(Figure 9B) [22].
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Figure 9. 670nm light decreases EAE severity in WT mice but not IL10-deficient mice.
Previous data demonstrates the protective nature of the light therapy in WT mice expressing
IL-10 in comparison to the increased clinical scores of the IL-10-/- mice. These data implicate
IL10 as important in protection from EAE mediated by 670nm.
(Muili et al., 2012)

Hypothesis
Multiple sclerosis is a disease plaguing approximately 250,000 people in the US
alone [1]. Previous data demonstrated the therapeutic potential of 670nm light therapy
in the EAE model, in part through an immune mediated mechanism involving production
of IL10 and down-regulation of the pro-inflammatory response. The goal of this new
experiment is to identify the cellular source of IL10 implicated in the mechanism of
disease protection. This data will provide a deeper understanding of disease protection by
670nm light, which will be necessary as this is developed as an adjunct therapy for the
treatment of MS. The central hypothesis is that up-regulation of the anti-inflammatory
cytokine, IL-10, by 670nm-mediated photobiomodulation decreases disease severity in
the EAE model.
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Specific Aims
I. Investigate the role of immune modulation in the amelioration of EAE by
photobiomodulation.

II. Characterize the source anti-inflammatory cytokines in response to
photobiomodulation by visualizing what cells are releasing IL-10 through the
use of GFP reporter mice.

CHAPTER II: MATERIALS AND METHODS
Mice
Pathogen-free female WT, IL10 deficient (IL10-/-), and mice genetically modified
to express GFP following the IL-10 promoter on a C57BL/6 (B6) background were bred
in-house from breeding pairs purchased from Jackson Laboratories (Bar Harbor, MN).
The mice were housed in an Association for Assessment and Accreditation of Laboratory
Care (AAALAC) accredited facility on the University of Wisconsin-Milwaukee campus
following National Institutes of Health (NIH) and University guidelines. Food and water
was provided ad libitum and a 12-hour light/dark schedule was used in a temperature and
humidity-controlled environment. Protocols were certified by the Institutional Animal
Care and Use Committee. All mice used were 6-8 weeks of age.
GFP, originally found in the jellyfish Aequorea Victoria, has been widely used in
biochemical and cell biology studies to visualize proteins [3]. Through fusion with the
desired protein, GFP allows visualization of the protein while it maintains its normal
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functional properties. GFP fluoresces a vivid green color when exposed to blue light.
When conditions prompt the expression of IL-10 in the mice expressing GFP under the
control of the IL10 gene promoter, GFP will be expressed and the cells will glow
allowing the location of IL-10 to be visualized in genetically altered heterozygous
GFP/IL-10 mice.

Antigens
MOG35-55 peptides (MEVGWYRSPFSRVVHLYRNGK) synthesized and purified
by HPLC (GenScript, Piscataway, NJ) were used for the emulsion as well as in the
resuspension for the cell culture.

EAE induction
EAE was induced by active immunization with an emulsion made with MOG35-55
and Mycobacterium tuberculosis. The emulsion of 50 µg or 100 µg MOG35-55 peptide
emulsified (1:1) in incomplete freund’s adjuvant (IFA, MP Biochemicals, Solon, OH)
with 300 µg M. tuberculosis, strain H37RA (Difco Laboratories, Detroit, MI) was
injected into mature mice (6-8 weeks old). Emulsions were prepared using an Omni
Mixer Homogenizer (Omni International, Kennesaw, GA). Each mouse received 0.05
mL of emulsion subcutaneously at four sites. When immunized for clinical disease
course, mice also received 300 ng pertussis toxin (PT, List Biological Labs Inc.,
Campbel, CA) prepared in with phosphate buffered saline (PBS) to keep the disease onset
consistent throughout the mice. The PT/PBS mixture was injected intraperitoneally at 0
and 72 hours post immunization, per standard laboratory protocol.
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Before the mice were injected with the emulsion, they were anesthetized using a
ketamine (100mg/ml), xylazine (300 mg/ml) cocktail (1 ml ketamine; 0.15 ml xylazine;
4.6 ml water) which was injected intraperitoneally.

EAE clinical grading
Mice observed for clinical EAE beginning 7-10 days post immunization (dpi) and
continuing daily for the duration of the experiment. Mice were graded by a blinded
observer using a clinical scale of 0-5 [0: healthy, no sign of EAE; 1: loss of tail tone; 2:
hind limb weakness; 3: paresis or paralysis of one hind limb; 4: paralysis of both hind
limbs; 5: moribund or dead]. Mice receiving a clinical score of >4 were sacrificed.

Treatment
Once mice were deemed sick, (clinical score of 1) they were designated into
either the treatment group or sham group, receiving no light treatment. Treatment of 670
nm wavelength light was administered using a Gallium/Aluminum/Arsenide (GaAlA)
light-emitting diode (LED) array (75cm2) (Quantum Devices, Barneveld, WI) at 67%
intensity for 90 seconds at a power intensity of 28mW/cm2. During these treatments,
unanesthetized mice were placed in a polypropylene restraint (12.7 x9 x7.6 cm) with the
light placed directly above the dorsal surface of the mouse for the defined treatment time.
For sham treatment, the mouse was placed in the treatment chamber for the same length
of time as the groups receiving light treatment but without light exposure. This was to
account for the effect the stress of the restraining the mice may have.

Treatment was

applied once daily as follows: 7 days treatment, followed by 7 days rest, with 7 days
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treatment, and an additional rest period of 7 days. The mice received an energy density
of 5J/cm2 (375 J daily total).
For in vitro treatment experiments, Lymph node and spleen cells that had been
extracted and set up in a cell culture (see cell culture) were also designated to either the
treatment or sham group. The treated cells received treated with 670 nm wavelength
light at 100% intensity for 180 seconds using a hand held WARP 75 Light Delivery
System (Quantum Devices, Barneveld, WI). Treatment began 2 hours after the cells were
resuspended then every 24 hours for 3 days. During these treatments, the light was
placed 2 cm above the flask for the given treatment time. For sham treatment, the flask
was still placed in the treatment chamber for the same length of time as the groups
receiving light treatment but without light exposure.

Cell Culture
For in vitro characterization of the response to NIR treatment, lymph nodes and
spleen cells were isolated from mice immunized as above but with without PT 10-14 dpi
or over the course of disease, as indicated. Samples isolated over the course of disease
defined as follows: pre-clinical phase (~10 dpi) before clinical symptoms of EAE appear;
2 days post onset when clinical disease begins; during the peak of the disease (where
disease course is typically the worst); 2 days into the second rest period; and 2 days post
second treatment. Mice were sacrificed by anesthetizing them with the ketamine cocktail
and cervical dislocation. Using a dissection tray and sterile technique including reagent
grade ethanol, spleens and lymph nodes were removed and suspended separately in
Hank’s Balanced Salts (HBSS). Six draining peripheral lymph nodes (2 popliteal, 2
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axilliary and 2 brachial) were removed from each immunized mouse.

Single cells

suspensions were then generated through homogenization of the removed nodes and
spleens with autoclaved glass homogenizers.

These cells were then centrifuged at

1250xg for 10 minutes to separate the cells from fat and debris. Trypan blue was used to
visualize the cells (90 µl of 0.4% trypan blue; 10 µl cells) and determine cell viability
using a hemacytometer. The cell count was determined using the following formula:
(No. of cells counted) (Dilution factor) (104)/ No. of squares counted = cells/ml
A total of 2 X 106 cells/ml were then cultured in RPMI 1640 complete [penicillin
(100 U/mL)/streptomycin (100 µg/mL), L-glutamate (2 mM), sodium pyruvate (0.1 mM),
2-mecarptoethanol (50 mM)], 10% Fetal Bovine Serum (FBS), and MOG35-55 (10 µg/ml).
The suspension was then distributed into T75 tissue culture flasks (TPP tissue culture;
MidSci, St. Louis, MO); 670 nm light at 180 seconds and sham (e.g. no light) group and
antigen vs no antigen, and stored in an incubator at 35-37 degrees Celsius at 10% CO2.

RNA isolation
The cells harvested from spleens and lymph nodes (as described in cell culture)
were centrifuged at either 24, 48, 72, or 96 hours after incubation. The cells were then
homogenized in 1 ml of Trizol reagent (Invitrogen, Grand Island, NY) and frozen at -80
°C until further use.

Total RNA was isolated by the Trizol method, according to

manufacturer’s instructions. Briefly, the frozen cells were allowed to thaw at room
temperature and centrifuged at 12,000xg for 10 minutes at 2-8 °C. Chloroform (200 µl)
was added for every 1 ml of Trizol and the cells were vigorously shaken for 15 seconds,
incubated at room temperature for 2-3 minutes, then centrifuged at 12,000xg at 2-8°C for
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15 minutes. The upper aqueous layer containing the RNA was carefully removed and
placed in a clean tube. 0.5 ml isopropanol per 1 ml Trizol added to the original cell
solution and mixed gently, followed by a10 minute incubation at room temperature. The
RNA was recovered through centrifugation again at 12,000xg at 2-8°C for 10 minutes.
The supernatant was removed and the RNA was washed with 1 ml of 70% ethanol
(EtOH) for every 1 ml Trizol. The samples were again centrifuged at 75,000xg for 5
minutes at 2-8 °C. The supernatant was carefully removed and the RNA pellet was
allowed to air-dry and resuspended in 50 µl molecular grade water. The concentrations
and purities of the samples were assessed using a UV-2501 PC UV-VIS recording
spectrophotometer (Shimadzu Scientific Instruments Inc.) using absorbances at 260 nm
and 280 nm. The samples were diluted 1:50 in 1X TE buffer (10mM Tris-HCl, 1 mM
EDTA, pH 7.5). When necessary, RNA was concentrated using the Qiagen RNEasy MinElute colums, according to manufacturer’s instructions (Qiagen, Valencia, CA). Total
RNA concentration was adjusted by dilution to assure reverse transcription of similar
amounts of RNA for QPCR analysis.

Reverse Transcription
The isolated RNA samples were reverse transcribed (RT) to cDNA using the RT 2
HT First Strand Kit (SA Biosciences, Valencia, CA) according to manufacturer’s
instructions. Six microliters of genomic DNA elimination buffer (GE2) was added to 8
µl of RNA and allowed to incubate at room temperature for 10 minutes. Following the
incubation, 6 µl of RT Master Mix (BC5) was added. Reverse transcription was carried
out using the Mastercycler Gradient PCR machine (Eppendorf’s Scientific, Hauppauge,
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NY) at 42 °C for 15 minutes then 95 °C for 5 minutes. Molecular grade water was added
at a volume of 91 µl and the samples were stored at -20 °C until use.

Quantitative Real-time PCR
Real-time Quantitative PCR (RT-qPCR) is used to amplify and quantify the
amount of template (cDNA or DNA) in a sample. RT-qPCR allows for quantification to
happen in real time after each amplification cycle and is paired with reverse transcription
to quantify messenger RNA (mRNA). The ΔΔCT (threshold cycle) programming was
used in which fluorescence is used to determine if the sample surpasses a given threshold.
This technique was performed using SABiosciences primers and RT2 SYBR Green qPCR
master mix reagents to determine gene expression. Samples that have undergone RT
were used following manufacturer’s instructions. Beta-actin (β-actin) was used as a
housekeeping gene while IL-10, INF-γ, and IL-4 primers were used to quantify IL-10,
INF-γ, and IL-4 expression. The primers were designed to span introns when possible
and were purchased from Sigma (St. Louis, MO). Each reaction was run in triplicate
with water blanks set as controls. The reaction mixture for a single reaction was set up as
follows in Table 1:
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Table 1. qPCR
Component

Volume (µl)

RT2 SYB® Green qPCR master mix

12.5

Primer Set

1

Molecular grade H2O

10.5

Total Volume

24

For each reaction, 1 µl of the sample RNA was added to 24 µl of the above
mixture. Assays were performed using StepOnePlus RT-PCR from Applied Biosystems
(Carlsbad, CA). Instrumentation was programmed for a hot start of 95 °C for 10 minutes.
The amplification ran for a total of 40 cycles which included 95 °C for 15 seconds and 60
°C for 1 minute. A melt curve was programmed for 95 °C for 15 seconds, 60 °C for 1
minute, and 95 °C for 15 seconds. Expression was quantitated via the Pfaffl method and
normalized to β-actin. Unlike the ΔΔCT model which assumes 100% efficacy between
the primers, the Pfaffl method uses a standard curve of each primer to determine
efficiencies to aid in the analysis [71].

Enzyme-Linked Immunosorbent Assay
Cell culture supernatants were acquired at 48, 72, and 96 hours and subjected to
cytokine analysis using enzyme-linked immunosorbent assay (ELISA). The cytokines of
interest were IL-10, IFN-γ, and TGF-β. ELISAs were performed per manufacturer’s
instructions using the Ready-Set-Go kit from eBiosciences (San Diego, CA). ELISA’s
are used to detect and quantify specific proteins that have been secreted from cells.
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Using a high binding affinity, the ELISA plate captures the target protein, which is then
detected by a protein-specific biotinylated antibody. Quantification is done through a
colorimetric reaction based on activity of avidin-horseradish peroxidase (HRP).
Before beginning the ELISA, the 96-well plate was coated overnight with 1x
dilution of the capture antibody in 1x coating buffer at 4°C. The wells were then washed
5 times with 100 µl wash buffer (PBS and 0.05% Tween-20) per well. The wells were
then blocked with 200 µl 1x Assay Diluent and incubated at room temperature for 1 hour.
The plate was again washed and 100 µl of the standards or each sample was added to
each well and incubated at room temperature for 2 hours. The wells were washed and
100 µl of detection antibody was added and the plate was again incubated for 1 hour at
room temperature. Following incubation, the plate was washed and 100 µl Avidin- HRP
diluted in 1x Assay diluents was added to each well and incubated at room temperature
for 30 minutes. After a final wash cycle, 100 µl of tetramethylbenzidine (TMB) substrate
solution was added to each well and incubated for 15 minutes. After, 50 µl of stop
solution (2.5N H2SO4) was added to each well and the plate was read at 450 nm within 30
minutes of adding the stop solution.

Flow cytometry
Cells acquired from spleens and cultured and treated as previously discussed were
analyzed by flow cytometry to characterize the phenotype of responding cells. After the
final light treatment, cells were incubated for an additional 2 hours to allow for
transcription to take place. The cells were then counted for viability using trypan blue, as
previously described. Using Lymphocyte Separation Medium (9.4 g sodium diatrizoate,
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6.2 g ficoll per 100 ml of LSM) the cells were place over a density-dependent gradient to
separate mononuclear cells. In this process, the cell suspensions were overlaid on 5 ml
LSM and centrifuged for 30 minutes at 500xg at 4°C (with the break turned off). The
interface was then removed and diluted 1:2 with HBSS and underwent two additional
washes using HBSS. Again, the cells were then counted for viability and aliquotted into
1.7 ml tubes at a cell count of 2.0x106.
The aliquotted cells received 5 µl FC block (eBiosciences, San Diego, CA) to limit
the amount of non-specific binding through the FC receptors and were incubated on ice
for 30 minutes. The cells underwent two washes and were resuspended in 50 µl FACS
wash buffer (0.5% PBS, 0.1% FBS, and sodium azide) and were incubated on ice for 30
minutes with 1 µl of a designated antibody for cell surface markers.
The cells were stained as follows:

Table 2. Flow Cytometry Cell Markers
FITC (FL1 channel)

PE (FL2 channel)

PerCP (FL3 channel)

APC (FL4 channel)

CD3

CD19

Foxp3

CD25

CD3

CD4

Foxp3

CD25

CD3

CD8

Foxp3

CD25

Rat IgG2a

Rat IgG2b

Controls
Rat IgG2a

Rat IgG2b

Cells were labeled with antibodies to identify T cell populations (CD3, CD4,
CD8, CD25, and FoxP3), B cell populations (CD19), as well as macrophages (CD11b)
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and neutrophils (Ly6G). Species, isotype, and fluorochrome matched antibody controls
were also used, as well as single-labeled controls to allow for proper compensation using
the flow cytometer. Cells expressing IL-10 were identified by virtue of green
fluorescence. The phenotype of IL10-producing (e.g., green fluorescing) cells were
identified by virtue of interaction with specific antibodies, as outlined above.
The antibodies were purchased from Biolegend (San Diego, CA) and eBioscience
(San Diego, CA). Foxp3 is an intracellular stain in which the cells were first stained
using surface markers, then underwent permeabilization for intracellular staining.
Following the last wash with the surface markers, the supernatant was discarded and the
sample was vortexed to dissociate the pellet. 1 ml of Foxp3 Fixation/Permeabilization
working solution (eBiosciences, San Diego, CA; 1 part fixation/permeabilization
concentrate with 3 parts fixation/permeabilization diluent) was added to each sample and
vortexed. After a 30 minute dark incubation at 4 °C, 2 ml of 1x Permeabilization Buffer
(1ml permeabilization buffer in 9 ml distilled water) were added to each sample. The
supernatant was then discarded after centrifuging the cells at 400xg at room temperature
for 5 minutes. The cells were then resuspended in 100 µl 1x Permeabilization Buffer
with 1 µl of PerCP-Cy5.5 Foxp3 antibody and incubated in the dark for 30 minutes on
ice.

Following the incubation, the samples underwent 2 washes with 2 ml 1x

Permeabilization Buffer and resuspended in 500 µl FACS wash buffer, ready for analysis
using flow cytometry.
The data were collected using a dual laser BD FACS Calibur (BD Biosciences,
San Jose, CA) using the computer program CellQuest Pro (BD Biosciences, San Jose,
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CA). After the data were collected, analyses were run using FlowJo software (Tree Star,
Ashland, OR).

Microarrays
Complimentary DNA (cDNA) from the two groups (treated vs. sham) were
further investigated using microarrays. Microarrays are used to measure the expression
levels of genes simultaneously using a fluoriphore-labeled target. Using a hybridization
protocol from Qiagen (Valencia, CA), gene expressions from both groups were
compared. The use of this technique allows for analysis of genes whose expression has
been changed during the course of MS/EAE due to photobiomodulation with 670nm
light. Specific time points of sham and treated cells were analyzed using two kits: Th17
for Autoimmunity and Inflammation and Nitric Oxide Signaling Pathway, (Qiagen,
Valencia, CA). 96h samples from our sham and treated cell pellets from cell culture were
compared using the Th17 kit to look at inflammatory and autoimmune cytokine
expression levels. Our 48h samples used the nitric oxide signaling pathway to compare
gene expression levels in our sham and treated samples.

Statistical Analysis
Data were analyzed and statistical analyses were carried out using GraphPad
Prism 5.0 (La Jolla, CA) or FlowJo software (Tree Star, Ashland, OR). Clinical scores
were analyzed using 2-way ANOVA.
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CHAPTER III: SPECIFIC AIM I

Investigate the role of immune modulation in the amelioration of EAE by
photobiomodulation.

Rationale
While the current paradigm describes MS/EAE as autoimmune diseases mediated
by myelin-reactive CD4+ Th1/Th17 cells, recent data suggest that the axonal loss
associated with disease progression is mediated by oxidative stress. The currently
approved therapies are of limited effectiveness, probably because they fail to prevent the
accumulation of oxidative stress leading to axonal loss. Photobiomodulation has proven
effective in the treatment of chronic inflammation and neurodegeneration through
remediation of oxidative stress. Our published data demonstrated the therapeutic potential
of 670nm-mediated photobiomodulation in part through an immune-mediated
mechanism. Given the role of the immune response in MS/EAE pathogenesis, a better
understanding of the effect of photobiomodulation on the immune response is necessary
in order to proceed to clinical studies in the MS patient population.
Through the use of cell supernatants, in which protein are found, ELISAs were
performed to look at gene expression. QPCR and microarrays looked at the cell pellet,
which contains mRNA to analyze the message for protein synthesis. Preliminary data
showed up-regulation of IL-10 with down-regulation of INF-γ protein expression by
ELISA when antigen-primed lymph node cells were exposed to NIR light at a
wavelength of 670 nm [22]. Transcriptional up-regulation of IL-10 and down-regulation
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of IFN- by QPCR analysis was also noted in the spinal cord of 670nm light treated mice
over the course of MOG-induced EAE. The role of IL-10, and global regulation of
inflammation, in the amelioration of EAE by 670nm light phototherapy was further
investigated.

Research Design
Female WT and IL-10-/- mice of the C57/BL6 background were immunized with
100µg MOG35-55 emulsified in Freud’s incomplete adjuvant mixed with M. turberculosis
H37RA. Treatment began immediately after immunization and continued for 10 dpi. On
the first day of treatment the mice were assigned to the 670nm NIR-LED treated or sham
group, and were treated accordingly using the suppression treatment protocol. Using a
pre-determined clinical scale, disease severity was recorded daily throughout the
experiment.
Both treated and sham mice were placed in a polypropylene restraint for the
duration of the defined treatment time (90s or 180s). The sham mice, receiving identical
treatment without the administration of light, served as the control population. Mice
receiving the NIR-LED therapy at 67% intensity for 180s received 10J/cm2 on the dorsal
surface. At the end of the experiment, mice were sacrificed and their clinical grades were
normalized to the day of onset for analysis. In order for statistical significance to be
achieved, anywhere from 20 to 40 mice were immunized to assure that each treatment
group had at minimum 10 mice.
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For cytokine and QPCR analysis, draining peripheral lymph nodes and spleens
were removed from mice 10 dpi and set up in cell culture receiving 670nm light or no
light. The cells were treated and harvested at 24 hour intervals for a total of 96 hours.

Results
Cytokine analyses by ELISA shows a up-regulation of IL-10 protein in cells introduced to
photobiomodulation
Lymph node cells cultures receiving 670nm light treatment as previously
described show a down-regulation of IFN-γ in comparison to the sham controls at 48h
and 96h [22]. In the current study, the largest decrease of IFN-γ was seen at the 96h time
point (Figure 10A). This agrees with our published data of spinal cord analysis with
ELISA analyzed throughout the course of the experiment [22], particularly with the
QPCR data obtained 2 days post secondary treatment (Figure 8). Conversely, IL-10
production was up-regulated in the presence 670nm light, however, maintained the level
of production throughout the course of the experiment (Figure 10B).
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Figure 10. Up-regulation of IL-10 in the presence of 670nm light. ELISA analyses of IL-10
and IFN-γ at 48h and 96h time points show a decrease in IFN-γ production with a
subsequent increase in IL-10 levels when 670nm light as administered. IL-10 levels within
the two groups remain constant throughout the duration of the experiment. 670nm light
impacts the production of pro- and anti-inflammatory cytokines.
(This experiment must be replicated as these results are compiled from a single experiment,
thus accounting for the lack of error bars.)

QPCR analysis indicates a down-regulation of IL-10 mRNA in the presence of 670nm
light
QPCR analysis of cDNA from lymph node cells treated as previously indicated
showed a down-regulation of message for both IFN-γ and IL-10 cytokines.
Contradictory to what was previously shown from in vivo analysis of cytokines through
QPCR, the in vitro study of lymph node cells indicate that the light is not only downregulating IFN-γ but having the same effect on IL-10 production when normalized to the
sham control (Figure 11). This indicates that the light has a different effect on translation
by increasing gene expression, than on transcription.
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Figure 11. QPCR analysis shows down-regulation of IFN-γ and IL-10. QPCR analysis from
cell cultures from spleen cells show a down-regulation of both pro- and anti-inflammatory
cytokines in the presence of 670nm light. 670nm light therapy down-regulates IL-10

Microarrays

production in vitro.

670nm light globally down-regulates inflammatory markers in vitro
Microarray analysis was performed on 96h cDNA obtained from lymph node
cells. This microarray tested 96 different genes and cytokines involved in pro- and antiinflammatory processes. The 670nm light experimental group, normalized to the sham
control, resulted in 2-3 fold increases of anti-inflammatory genes, with a 2-5 fold
decrease of pro-inflammatory genes (Table 3). Chemokine ligand 7 (CCL7), a regulator
of macrophages, and chemokine ligand 1 (CXCL1), displaying neuroprotective functions,
were both up-regulated in the presence of 670nm light. IL-17a, a pro-inflammatory
cytokine that enhances the production of NO was also increased.
Figure 12 shows a scatter plot of the genes and cytokines that were analyzed with
the microarray. Analysis of 96h 670nm cDNA was normalized to the sham control.
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Placing the parameters at a 2-fold increase allows for better visualization of these
cytokines affected by the light. A marker has also been placed to indicate IL-10 within
the plot. Again, indicating that the transcription of IL-10 is unaffected by the light
treatment.

Figure 12. Scatter plot analysis from inflammatory microarrays. Emphasizing a 2-fold
increase, the scatter plot displays the cytokines both increased and decreased in the
presence of 670nm light. 670nm light decreases IFN-γ production.
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Decreases were found in JAK3 and TBX21, both transcription factors for IFN-γ,
IL-21, which is regulated by JAK3, and subsequently IFN-γ. These results agree with the
findings from preliminary data that IFN-γ is down-regulated in the presence of the light
therapy [22]. Overall, the down-regulations seen agree with the understanding that
670nm light decreases or inhibits pro-inflammatory processes.

Table 3. Gene and cytokine fold changes in microarray analysis of 96h 670nm treated sample
in comparison to the 96h sham control.

The nitric oxide signaling pathway microarray, performed on the 48h lymph node
samples, was normalized to the sham control. Figure 13 is a scatter plot that highlights
the signaling markers that fall outside of a two-fold increase. Up-regulation was seen in
signals that produce ROS (NOXA1) and free radicals (NOS2) lending to the mechanism
of the light. Up-regulation was also seen in those that display protective qualities such as
preventing against peroxidation (GPX5) and oxidative stress (UCP3). Down-regulation
of signals were much more prevalent than up-regulation. Down-regulation was seen in
CAPNS1, in which activation is triggered by oxidative stress, DYNLL1, which
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destabilizes nitric oxide synthesis, GPX1, an antioxidant, as well as PRDX2, which plays
an antioxidant protective role.

Figure 13. Scatter plot analysis from NO signaling microarrays. Emphasizing a 2-fold
increase, the scatter plot displays the signaling molecules both increased and decreased in
the presence of 670nm light. 670nm light briefly up-regulates ROS.
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Table 4 shows an itemized list of the signaling molecules that were regulated by
at least a two-fold increase or decrease in the presence of 670nm light therapy when
normalized to the sham control.

Table 4. NO signaling molecule fold changes in microarray analysis of 48h 670nm treated
sample in comparison to the 48h sham control.

Discussion
Previous data from our lab has shown a decrease in disease severity in WT mice
receiving 670nm light therapy. Results have also showed that in the presence of light,
IL-10-/- mice display the same disease course as their sham counterparts in comparison to
the WT treated mice who display a less severe disease course than the WT sham mice
(Figure 9) [22]. This is indicative of a protective role afforded through light therapy
through the action ofIL-10. This hypothesis is further supported by in vitro cytokine
analysis.

ELISA data demonstrated that 670nm light-treated cultures displayed a
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decrease in IFN-γ production and an increase inIL-10 over the course of 96h culture
(Figure 10). Agreeing with this data, IFN-γ levels in QPCR as well as microarray
analyses were also decreased when treated with 670nm light.
The current studies utilized QPCR microarray to investigate the effect of 670nm
light treatment on inflammation at a global level. The microarray utilized allowed for 96
different genes to be analyzed at one time. In addition to a decrease in IFN- γ expression,
molecules important the regulation of IFN or regulated by IFN were also decreased,
including TBX21, a transcription factor for IFN- γ, and JAK2, a kinase regulated by IFNγ. In addition IL-21, a cytokine that uses that JAK/STAT pathway was also downregulated. Not only is the light therapy responsible for the production of protective
cytokines, it is also responsible for a down-regulation of the transcription factor as well
as the pathway for IFN-γ production. This is indicative of the protective role afforded by
the light therapy. A down-regulation is also seen in colony-stimulating factor 3 (CSF3)
which controls the production, differentiation, and function of granulocytes.
Up-regulation of CXCL1 displays beneficial qualities toward the amelioration of
MS/EAE. Omari et al. found that mice with increased levels of CXCL1 display milder
forms of EAE than those at normal or below normal levels [72]. Mice displaying higher
CXCL1 had decreased inflammation and demyelination, suggesting a neuroprotective
role for CXCL1 [72].
As mentioned earlier, photobiomodulation (PBM) briefly up-regulates ROS and
NO, which increases production of NF-κB, involved in the production of protective
genes. Due to the findings of this microarray, we can attribute this up-regulation of NO
to IL-17a. IL-17a regulates NF-κB through enhanced production of NO [70].
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Our previous data demonstrated up-regulation of IL-10 protein expression by
ELISA. However, IL-10 mRNA expression was decreased compared to the Sham control,
as demonstrated by QPCR and microarray analysis. These apparently contradictory
results could be explained by a number of factors. First, could be due to the fact that IL10 is regulated at the transcriptional and post-transcriptional levels [73]. Transcription is
responsible for converting DNA into RNA, and is the first step in the gene-making
process. Post-transcription is the regulation of gene expression at the RNA level. In
post-transcription, mechanisms are put in place to extend the half-life of the RNA
molecule and protect it from degradation. These modifications allow for faster, more
complete protein synthesis. In a traditional sense, if transcription is increased, translation
would increase resulting in higher gene expression. At the post-transcriptional level, if
transcription remains constant, messenger RNA (mRNA) would remain the same. Posttranscriptional modifications can be made at this point which can alter the level of protein
expression from single mRNA molecules. Another reason for this discrepancy could be
that both QPCR and microarray analyses are merely snapshots of gene expression at a
given time. The fact that IL-10 levels are higher in the ELISA may indicate that the 96h
time point was too late to capture maximum IL-10 message expression.
The fact that IL-10 production shows an increasing trend in the QPCR analysis
may simply indicate that we are not allowing enough time between treatment and the
harvesting of cells.

In the current experiments, the cells were harvested 2h after

treatment to allow for translation to occur. Again, we know that the light temporarily
increases NO in order to activate signaling pathways toward protective gene expression.
Microarray analysis at 96h is still associated with increased NO, perhaps due to the
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production of IL-17a. This indicates that two hours after treatment may not enough time
for the transcription factors to respond and generate increased gene expression. Perhaps
harvesting the cells at later time points will allow enough time for the message to be
translated, because as it stands, two hours disrupts signaling before the translation can
have an effect on gene expression.
The decrease in IFN-γ through the down-regulation of its transcription factor is
one way the light therapy is offering protection. Although not enough time was allowed
for the up-regulation of the protective cytokines to come to fruition, the initial steps
alluding to protection are seen, including up-regulation of IL-10.

CHAPTER IV: SPECIFIC AIM II

Characterize the source anti-inflammatory cytokines in response to photobiomodulation
by visualizing what cells are releasing IL-10 through the use of GFP reporter mice.

Rationale
It is accepted that anti-inflammatory cytokines ameliorate the severity of MS and
EAE. The FDA approved therapies, all active through immunomodulatory or
immunosuppressive mechanisms, function in least in part by inducing anti-inflammatory
cytokines. Data generated by this lab suggest that photobiomodulation induced by 670
nm light improves the severity of EAE at least in part through the production of IL-10
[22]. Because the production of IL-10 is known to amelioration clinical EAE, it is
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important to know which cells are responsible for the synthesis of IL-10 in an infected
mouse.

Thus, draining peripheral lymph node and spleen cells from MOG35-55

immunized mice were analyzed by flow cytometry to identify the immune cells
responsible for the secretion of IL-10 induced by 670 nm-induced photobiomodulation.

Research Design
Female mice of the C57/BL6 background expressing GFP under the control of the
IL-10 promoter, and WT mice were immunized with 100µg MOG35-55 emulsified in
Freud’s incomplete adjuvant with M. tuberculosis H37RA at 4 dorsal sites. Mice were
sacrificed 10 dpi and draining peripheral lymph nodes and spleens were removed cultured
in vitro in the presence of antigen. The cells were subjected to either 3 days of NIR-LED
light therapy using a handheld WARP 75 Light Delivery System, or no light at all. After
the treatment period, the cells were stained with cell surface and intracellular makers to
identify B cells, T cells, and regulatory cells and subjected to analysis using flow
cytometry. To assure that a sufficient number of cells were attained for analysis, 4 to 7
mice were immunized for lymph nodes or spleen removal.

Results
Photobiomodulation induces IL-10 production.
Our previous data showed the up-regulation of IL-10 secretion by QPCR and
ELISA of cells and tissue isolated from 670 nm light treated, MOG35-55-immunized mice
over the course of EAE. Clinical data demonstrated that mice genetically deficient in IL10 lacked the ability to recover from EAE when treated with 670nm light therapy,
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confirming the importance of IL-10 in protection against clinical EAE afforded by 670
nm-mediated photobiomodulation.
To directly investigate the induction of IL-10 by 670 nm light, flow cytometric
analysis of lymph nodes extracted from 7 IL-10/GFP mice was performed. The analysis
was gated on the lymphocyte population using a forward vs. side scatter plot.

As

expected, an increase in IL-10 production was seen in the 670nm treated cells in
comparison to the sham controls (Figure 14).

Figure 14: 670nm light induces IL-10 production by lymphocytes. Lymph node cells from
MOG35-55 immunized mice were subjected to a 3 day light treatment (670nm) or received
no light treatment. Flow cytometry analysis gated on lymphocytes showed an increase in IL10 production in 670nm light treated cells compared to the sham control. Induction of IL-10
by 670nm light would be expected to protect against EAE.
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Because it is known that both B and T cells secrete IL-10, further analysis was
done to determine which of these lymphocytic populations were responsible for the 670
nm light-induced increase in IL-10 production. The results showed that CD3, not CD19
cells were responsible for the largest increase in IL-10 secretion (Data not shown). Thus,
subsequent studies focused on characterization of T cells.
Regulatory CD4+ and CD8+ T cells are known to secrete IL-10. To identify with
population of regulatory T cells was induced by 670 nm light, flow cytometric analysis of
draining lymph node cells was performed. Cells from IL-10/GFP immunized mice were
labeled with CD8, CD4, and CD25 surface markers, and the analysis was gated on the IL10+ lymphocytes. The highest increase is found in CD8+CD25- cells (Figure 15B). There
was also a modest increase in CD4+CD25+ and CD4+CD25- cells of the light treated
cultures (Figure 15D).
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Figure 15: Increased production of IL-10 in lymphocytes induced by 670nm light. Two
populations of regulatory T cells – CD8+ and CD4+-- have been implicated in protection
against EAE. Lymph node cells isolated from MOG35-55 immunized mice were given a 3 day
light treatment (670nm) or no light treatment. Flow cytometry gated on IL-10 revealed an
increased population of CD8+CD25-IL-10+ cells induced by 670nm light. A modest increase in
IL-10 expression by CD4+CD25+ and CD4+CD25- cells in the treated group was also noted.
670 nm light induces a population of IL-10 expressing CD8+CD25- cells which could protect
against clinical disease.
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Photobiomodulation increases FoxP3 expression
Production of IL-10 by CD25+FoxP3+ regulatory T cells is well-characterized
[74]. To further investigate the induction of regulatory T cells by 670 nm light, spleen
cells from 6 WT immunized mice were labeled with CD8, CD4, and CD25 extracellular
markers as well as the intracellular marker, FoxP3, to look at potential Treg involvement.
Looking at FoxP3 expression gated on CD3 cells, we noted an increase of FoxP3 in cells
cultured with antigen and treated with 670nm light, in comparison to those receiving no
light, or not cultured with antigen (Figure 16).

Figure 16: 670nm light in the presence of antigen induces Foxp3 expression. Spleen cells
from mice immunized with MOG35-55 were cultured with and without antigen and received
670nm light or no light for 3 days. Flow cytometric analysis gated on CD3+ T cells shows an
increase of Foxp3+ cells when exposed to antigen and 670nm light. Induction of FoxP3
expression by T cells exposed to 670nm light plus antigen suggests regulatory T cells may
play a role in disease protection afforded by 670nm light.
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Due to the fact that the CD8+ cells demonstrated the greatest increase in 670 nminduced production of IL-10, we wanted to see if this stood true for the cells producing
FoxP3. Using the same parameters but gating on CD8 and CD4, analyses show that the
FoxP3 producing cells are CD4 and not CD8 (Figure 17).

Figure 17: 670nm light induces Foxp3 expression in CD4+ T cells. Spleen cells from mice
immunized with MOG35-55 received 670nm light for 3 days. Flow cytometric analysis
gated on CD8+ or CD4+ T cells, respectively, shows an increase of CD4+Foxp3+ cells with
670nm light exposure. CD4+Foxp3+ T cells induced by 670nm light in the presence of
antigen could play a role in amelioration of EAE by 670nm light.

The phenotype of the CD4+ FoxP3+ cells was further analyzed. Gating on FoxP3+,
the expression of CD4 and CD25 was investigated in 670 light treated vs. sham treated
cells, cultured in the presence or absence of antigen. Analysis of the sham –Ag group
(e.g., the immunized control group) revealed a CD4+CD25-Foxp3+ population (Figure
18A).

The sham +Ag group has the same CD4+CD25-Foxp3+ population plus a

population of CD4+hiCD25- cells (Figure 18B). 670nm light treatment resulted in the upregulation of CD4+CD25+FoxP3+ cell population, expected to be regulatory T cells
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(Figure 18C). However, in the 670nm +Ag group there is also a CD4+hiCD25- population
(18D).

Figure18: Induction of CD4+CD25+Foxp3+ cells by 670nm light treatment. Spleen cells from
MOG35-55 immunized mice cultured with and without antigen were treated with light
(670nm) or no light for 3 days. Flow cytometric analysis of populations gated on Foxp3 +
lymphocytes shows an up-regulation of CD4+CD25+Foxp3+ T cells in the light treated cells
compared to the sham controls. There is also an up-regulation of CD4+CD25-Foxp3+ T cells
with 670nm light. Induction of CD4+CD25+Foxp3+ cells, expected to be regulatory T cells, by
670nm light would be expected to reduce autoimmunity in EAE.
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Discussion
Preliminary data has shown the beneficial effect that light therapy has on
decreasing the clinical severity of EAE. In the study by Muili et al., as well as our
findings from the first specific aim, this decrease in disease is seemingly due to the
increase of IL-10 followed by a decrease in pro-inflammatory cytokines afforded through
the use of PBM [22]. The next logical step, then, was to determine the cells that, in the
presence of the light therapy, were responsible for the secretion of IL-10. The use of
GFP aided in this finding because of its interaction with the IL-10 promoter. Therefore,
every time IL-10 gene is transcribed GFP will be attached. Because our mice are bred inhouse, it is important that a homozygous WT female is bred with a heterozygous
GFP/WT male to ensure that the mice are IL-10/GFP heterozygotes.
Through the removal of spleens and lymph nodes of immunized mice, cells could
be stained for specific surface markers. This fluorescence-activated cell sorting (FACS)
analysis is used as yet another confirmation that the 670nm light is inducing a population
of IL-10 producing cells. What differentiates FACS from the other conformational tests
is that it allows us to look further into what cells in particular are involved. By staining
the cells with the surface markers CD3, CD4, CD8, CD19, and CD25 we were able to
distinguish what cells were involved in the highest production of IL-10 in the presence of
the light therapy. It is important to note that B cells are involved in the production of IL10; however, the light therapy has no effect on the up-regulation of these cells. While
further analysis on the therapeutic role B cells play in MS/EAE may be looked at down
the road, these results ultimately led to the investigation of T cells.
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Gating on the IL-10 population, the highest increase of IL-10 production came
from CD8+CD25- cells (Figure 5). CD25 expression is typically linked to regulatory
immune cells in which CD25 expression occurs in the thymus (nTreg) or within the
periphery (iTreg) [48]. In CD4+CD25- cells, the expression of CD25 depends on the
secretion of IL-2 by antigen-stimulated T cells within the peripheral lymphoid organs
[74]. It is important to note, however, that there are circumstances in which Tregs may
lack, or lose, CD25 markers. Bonelli et al. demonstrated that CD4+CD25-FoxP3+ cells
display a suppressive function similar to CD4+CD25+FoxP3+ cells in a model of
autoimmunity [75]. To see if this was the case for the CD8+CD25- population, FoxP3
staining was done. As a reminder, FoxP3 is an intracellular marker typical of most
regulatory cells, specifically CD4+ Tregs and some CD8+ Tregs [75, 76]. The results
from this finding indicated that these CD8+ cells responsible for such a sharp increase of
IL-10 do not contain FoxP3. This does not mean, however, that they are not regulatory
CD8+ cells. Because CD8+ Tregs have not been investigated as much as CD4+ Tregs, the
specific markers of regulation have not been fully established, and FoxP3 expression may
not be a specific marker for CD8+ Tregs [76]. The majority of FoxP3-expression is
linked to MHC class II restricted CD4+ cells [76]. In a study by Trandem et al., it was
hypothesized that IL-10 production from CD8+ T cells may be another mechanism in
place to diminish destruction of tissues in models of acute encephalitis or it may be used
as a self-regulation of CD8+ production [77]. Further analysis of these cells would need
to be done to determine regulatory functions or the possible relationship between
cytotoxic CD8+ T cells and IL-10 production.
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While the largest increase of IL-10 was seen in CD8+CD25- T cells, we chose to
investigate the role of FoxP3 expression in CD4+ T cells in the presence of 670nm light
because more research has gone into the expression of these cells. In putative CD4+
regulatory cells, FoxP3 expression is up-regulated in the presence of 670nm light (Figure
7). By gating on the population of FoxP3, Figure 9 looks at CD4 and CD25 markers to
further identify these cells. In the sham –Ag group, in which the cells are only exposed
to the self-reactive peptide at immunization, CD4+CD25-FoxP3+ cells are present. There
are conflicting views as to the functionality of this population of cells. The majority of
the characterization of these cells has occurred in systemic lupus erythmatosus, a
systemic autoimmune disease.

In a published manuscript from Yang et al. this

CD4+CD25-FoxP3+ population, as well as CD4+CD25lowFoxP3+ cells, were identified to
be distinct from Tregs, not only phenotypically, but through the production of increased
IL-2 and are, therefore, activated T cells [78]. Bonelli et al., however, found these cells
to resemble functional Tregs in vitro [75]. In this study, they also found that this
population of putative Tregs did not display increased levels of IL-10 or TGF-β,
indicating that these cells are not cytokine mediated [75]. What they concluded is that
these cells resemble a population partially functioning of Tregs [75]. Including the Ag in
the sham culture resulted in an induced population of CD4lowCD25-FoxP3+ cells.
The exact role and relationship of these two different populations has yet to be
established.

However, because these cells are acquiring FoxP3 expression in the

periphery (i.e. iTregs) there is clearly a maturation process that must occur. In this
instance, it is possible that FoxP3 expression is acquired before CD25 expression, giving
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us this population of CD4+Cd25-FoxP3+ cells. This would indicate that these cells are
immature Tregs waiting for CD25 expression to maturate.
The CD4+CD25-FoxP3+ cells found in the sham group, seemingly acquire CD25
expression in the 670nm treated cells cultured in the absence of Ag (Figure 18).
Similarly, the CD4+CD25-FoxP3+ population in the sham +Ag group is less robust and an
increase of CD4+CD25+FoxP3+ cells, presumably Tregs, arise. These findings would
agree with hypothesis that these are immature Tregs acquiring CD25 expression in the
periphery. It would also go to stand that the 670nm light therapy induces this immature
population of putative Tregs to become fully functional Tregs.

CHAPTER V: DISCUSSION
Discussion
As the most common cause of neurologic disorders of early to middle adulthood,
multiple sclerosis and its complexities are of interest of many researchers [2]. Previous
research describes the disease as an immune-mediated demyelinating disease of the CNS,
initiated by MHC class II-restricted, auto-reactive T cells due to [32,64]. These T cells
are responsible for secreting pro-inflammatory cytokines (INF-γ and IL-17) important in
the pathogenesis of disease.

The exact mechanisms of the disease are unknown;

however, mitochondrial dysfunction [32] and oxidative stress [2] have been shown to
play a role in axonal loss. While many anti-inflammatory, immunomodulatory, and
immunosuppressive therapeutics demonstrate proven efficacy in the delaying the
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progression of the disease, there are no approved therapeutic agents which prevent or
reverse the disease [64].
Experimental autoimmune encephalomyelitis (EAE) is the primary animal model
for MS, sharing clinical, mechanistic, and histopathological aspects with MS. It should be
noted that as an animal model, EAE does have limitations. A major criticism of EAE is
that it is not a spontaneous disease.

While a spontaneous disease model has been

developed with transgenic mice, most EAE activation requires active immunization as
well as the use of an adjuvant to further induce disease [20, 79]. EAE has also been
criticized because the disease is often studied in in-bred animals, in which much of the
genetic heterogeneity has been removed. It can be argued, though, that this homogeny is
required for the reproducibility of the disease among generations of the animals [20].
Preliminary data in the EAE model suggests disease amelioration is possible
using 670 nm light therapy [22]. This was not only seen through a decrease of clinical
scores in 670 nm light-treated animals in comparison to sham treated mice, but also
found in pro-inflammatory/anti-inflammatory cytokine ratios [22]. The current studies
further investigated the mechanism of immune modulation by 670nm-mediated light
therapy. Our ELISA data show up-regulation of IL-10 and a down-regulation of IFN-γ in
the 670nm treated group. In the presence of the light, the gene expression of IL-10 is
increased. QPCR analysis shows trends of increasing IL-10 production in the presence of
light. An increase in IL-10 production was also increased in the presence of 670 nm light
in our FACS and ELISA analyses, as well as with ELISA and QPCR analyses in recent
published data [22]. Decreased IL-10 expression levels in our 670 nm light group in
comparison to the sham group when analyzed using QPCR between the current data and
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that previously published by this laboratory may be due to differences in experimental
design.

Previous QPCR data from Muili et al., demonstrating increased anti-

inflammatory and decreased pro-inflammatory cytokines with 670nm light treatment was
performed on spinal cords of treated mice extracted throughout the course of the
experiment [22]. The current studies were performed on lymphoid cells isolated from
immunized mice and treated in vitro. It is important to note that IL-10 production is not
limited to lymphocytes. Through the removal of spleens and lymph nodes for the in vitro
analyses, we are targeting B and T cells and looking at the effects the light has on these
cells specifically. While there is certainly a case for the regulatory effects of the light
within these two cell populations, perhaps the spiked increase in the in vivo analyses is
due to non-lymphocyte cells, such as astrocytes or microglia, reacting to the light to
produce IL-10 as well [80].
The protective nature of the light therapy could be due to either a down-regulatory
effect that the light has on pro-inflammatory cytokines, an increase in IL-10 afforded by
the light that results in shifting the environment to a more anti-inflammatory disease
state, or, most likely, both factors. This is supported by the findings from ELISA data
that showed an increase in IL-10 production with a decrease in IFN-γ (Figure 10), and
QPCR analysis that shows that even when IL-10 levels are low, IFN-γ levels continue to
decrease (Figure 11).
It is reasonable to believe that harvesting cells 2h post treatment does not allow
enough time for transcription to take place. This is also supported by the fact that upon
light exposure, an initial spike in ROS and NOS occurs in order to prompt transcription
factors to produce protective genes [70]. Eventually the ROS species will be decreased
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resulting in long term protection. The microarray at 96h (Figure 12) showed increased
levels of IL-17A, which is known to be responsible for the up-regulation of NO [81],
indicating that transcriptional processes were merely beginning to take place, not
allowing enough time for translation to occur.

Because it is known that IL-10 is

regulated primarily by transcription and post-transcriptional factors [73], allowing more
time for the light to take full effect would presumably increase IL-10 expression.
Due to our findings that 670nm light had little effect on B cells we chose to focus
on IL-10 production in Tregs. Supported by a study by Matsushita et al., up-regulation of
Tregs or IL-10 production through Tregs after disease onset will prove to be most
beneficial in disease amelioration [42]. The study by Matsushita et al. proposed that
Bregs reduce disease severity during EAE initiation and Tregs inhibit the late stage
effects of MS [42]. The deletion of Bregs before immunization resulted in a more severe
disease than when Bregs were deleted during EAE progression. Similarly, the deletion of
Tregs had no effect on disease onset, but severely exacerbated the disease in later stages
[40].
While further characterization of the putative Treg population is necessary, our
data suggest that the light is inducing iTregs to produce IL-10. This is due to the fact that
FoxP3 expression levels increased in the presence of the light. The light also affected the
production of CD25+ cells as well. A population of CD4+CD25-FoxP3+ cells found in the
sham controls, presumably immature Tregs, gain CD25 expression when light was
administered. Through the induction of CD25 on these cells, the population is thought to
mature to become functional Tregs.

While more studies are necessary to confirm
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findings, the cells responsible for the up-regulation of IL-10 are likely responsible for the
decrease in clinical disease severity seen in in vivo experiments.

Future Directions
To continue this study, a number of experiments must be performed. More
experiments of in vitro studies needs to be done to understand the effect the light has on
message and protein expression of IL-10. There needs to be further clarification on the
potential decrease of message and increase gene expression of IL-10 seen in QPCR
analysis. A longer incubation period between treatment and cell harvesting may allow
for more complete transcription and translation. From there, characterization of the
CD4+CD25-FoxP3+ and CD4+CD25+FoxP3+ populations must be done to verify
suppressive properties. Characterization can be done through co-culture and transwell
assays. Further investigation of the IL-10 producing CD8+ T cells and their role in the
amelioration of EAE would also be beneficial in understanding disease amelioration
through the use of 670 nm light. An adoptive transfer experiment could be done once it
is determined what cells are most beneficial in the amelioration of EAE. These cells
would be transferred into a recipient host in hopes of transferring the immunologic
benefits of the disease, or induce tolerance to the disease.
In vivo studies of IL-10-/- mice must also be repeated. Treatment through a
suppression protocol in these IL-10-/- mice would help to further understand disease
course.

In this protocol, the mice would be treated for 10 consecutive days after

immunization. This addresses the issue concerning at which time point is treatment is
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most beneficial; treatment before disease onset, or treatment throughout the disease
course.

Conclusion
Photobiomodulation has the potential to decrease MS/EAE disease severity
through the up-regulation of IL-10 and down regulation of IFN-γ. While the largest
increase of this IL-10 production was seen in CD8+CD25- cells, increased production of
FoxP3 led our analyses toward CD4+ T cells. While confirmation of this population of
putative regulatory cells is necessary, an increase in CD4+CD25-FoxP3+ T cells appear to
be responsible for the decreased disease severity found in WT mice receiving 670nm
light therapy.

With this knowledge, PBM is a promising adjunct therapy in the

amelioration of MS.
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